Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

$26.4 million). The increase in interest expense follows the acquisition of New River which was partly funded by $1.3 billion of term loans, utilized under the $2.3 billion Multicurrency Term and Revolving Facilities Agreement. These term loans were subsequently partially repaid using the proceeds from Shire's $1.1 billion 2.75% convertible bond issued in May 2007. The remaining $200 million of the term loans was also repaid during June 2007. Interest expense for the year to December 31, 2007 includes a $7.9 million write-off of deferred financing costs following the repayment of these term loans.

In the years to December 31, 2007 and 2006 interest expense includes a provision for interest, which may be awarded by the Court in respect of amounts due to those ex-TKT shareholders who have requested appraisal of the acquisition consideration payable for their TKT shares. A trial date for the appraisal rights litigation has been set for May 12, 2008. Further information about this litigation can be found in our filings with the SEC, including our Annual Report on Form 10-K for the year to December 31, 2006 and our most recent Quarterly Report on Form 10-Q for the period to September 30, 2007.

Taxation

The effective tax rate for the year to December 31, 2007 was -4.0% (2006: 26.8%). Excluding the IPR&D charge of $1,866.4 million, which is not tax deductible, and the tax effect of items excluded from non-GAAP income as outlined on page 30, the effective rate of tax on non-GAAP income is 20.7% (2006: 26.8%).

The effective rate of tax under US GAAP in 2007 compared to 2006 benefited from: the tax effect of Shire plc's 2.75% convertible bonds; an increase in R&D tax credits; favorable permanent differences arising on the gain on sale of product rights and a net reduction in valuation allowances. These reductions to the effective rate of tax are partially offset by a net increase to the provision for uncertain tax benefits and associated interest a
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 New interactive learning ... thought leaders of the medical device industry at ... and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These all-new ... professionals practical presentations and implementable solutions on the ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
(Date:5/17/2013)... May 17, 2013 Tooth decay is an ... active signs of the disease. The World Health Organization says ... 100% of adults have cavities. What are the long-term effects ... showing a strong connection between the oral bacterial imbalance and ... disease so rampant, yet it is also 100% preventable? Answer: ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2
... data on lead NNRTI, RDEA806, and next generation compounds to be ... ... Calif., Jan. 29 Ardea Biosciences,Inc. (Nasdaq: RDEA ) today ... family of compounds,including RDEA806, RDEA427 and RDEA640, will be presented during ...
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... of Neoplastic Cells from Mixed Cellular,Compositions using ... cancer cells ex vivo from blood stem ... modified vaccinia viruses, herpes simplex,viruses, parapoxviruses and ...
... CALGARY, Jan. 29 /PRNewswire-FirstCall/ - SemBioSys Genetics ... of therapeutic,proteins for metabolic and cardiovascular diseases, today ... The Instituto de Agrobiotecnologia,Rosario S.A. (INDEAR) based in ... by Bio Sidus AG S.A. and Bioceres S.A. ...
Cached Biology Technology:Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 2Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 3Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent 2SemBioSys signs option agreement for safflower-produced food ingredient 2SemBioSys signs option agreement for safflower-produced food ingredient 3
(Date:5/16/2013)... genome-wide analysis (GWA), where the entirety of an individual,s ... or variants which can cause health problems is a ... can also pose major ethical problems if used incorrectly, ... Genetics (ESHG) published on line today (16 May 2013) ... Many services based on whole genome and on exome* ...
(Date:5/16/2013)... outside of the gym. But doctors use the human pulse ... Bao, a professor of chemical engineering at Stanford, has developed ... wider than a postage stamp. The flexible skin-like monitor, worn ... to help doctors detect stiff arteries and cardiovascular problems. , ... heart health and provide doctors a safer method of measuring ...
(Date:5/15/2013)... touting its benefit in moderating gout risk, new research ... not reduce uric acid (urate) levels to a clinically ... supplementation, alone or in combination with allopurinol, appears to ... in gout patients according to the results published in ... & Rheumatism . , Gout is an inflammatory ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3Vitamin C does not lower uric acid levels in gout patients 2
... the 2007 American Society for Microbiology (ASM) ICAAC Young ... Jason T. Blackard, Ph.D., Research Assistant Professor in the ... Medicine. Dr. Blackard is being honored for his ... Dr. Blackard is a highly qualified researcher, whose current ...
... 2007 American Society for Microbiology (ASM) ICAAC Young Investigator ... Ton-That, Ph.D., Assistant Professor in the Department of Molecular, ... Dr. Ton-That is being honored for his research ... Ton-Thats research is highly regarded, and has been published ...
... September 13, 2007 One of the 2007 American Society ... Merck and Company, Inc., U.S. Human Health, will be ... Professor in Pediatrics, Division of Pulmonary Pediatrics, Childrens Hospital ... is being honored for his research excellence in microbiology ...
Cached Biology News:
...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: